MX2020007860A - Tratamientos combinados para crisis de opioides. - Google Patents
Tratamientos combinados para crisis de opioides.Info
- Publication number
- MX2020007860A MX2020007860A MX2020007860A MX2020007860A MX2020007860A MX 2020007860 A MX2020007860 A MX 2020007860A MX 2020007860 A MX2020007860 A MX 2020007860A MX 2020007860 A MX2020007860 A MX 2020007860A MX 2020007860 A MX2020007860 A MX 2020007860A
- Authority
- MX
- Mexico
- Prior art keywords
- opioid
- effective amount
- alcohol
- medication
- death
- Prior art date
Links
- 238000011284 combination treatment Methods 0.000 title 1
- 229940079593 drug Drugs 0.000 abstract 5
- 239000003814 drug Substances 0.000 abstract 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 3
- 239000003187 aldehyde dehydrogenase inhibitor Substances 0.000 abstract 2
- 238000002483 medication Methods 0.000 abstract 2
- 208000012488 Opiate Overdose Diseases 0.000 abstract 1
- 208000027418 Wounds and injury Diseases 0.000 abstract 1
- 230000000202 analgesic effect Effects 0.000 abstract 1
- 230000006378 damage Effects 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 208000014674 injury Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000014 opioid analgesic Substances 0.000 abstract 1
- 229940005483 opioid analgesics Drugs 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Addiction (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Un método para reducir el riesgo de sobredosis relacionada con la medicación, muerte u otra lesión asociada con el consumo inapropiado de alcohol junto con analgésicos opioides de prescripción, que comprende: administrar un medicamento combinado que tenga una cantidad efectiva de uno o más medicamentos opioides y un cantidad de uno o más inhibidores de la aldehído deshidrogenasa, con el fin de proporcionar los poderosos efectos analgésicos del opioide junto con una sustancia que previene el consumo concomitante de alcohol, reduciendo así el riesgo de sobredosis de opioides mediada por alcohol o la muerte. Un medicamento combinado, que incluye una cantidad efectiva de uno o más medicamentos opioides, y una cantidad efectiva de uno o más inhibidores de la aldehido deshidrogenasa y un vehículo farmacéuticamente aceptable.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15/881,475 US10478408B2 (en) | 2018-01-26 | 2018-01-26 | Combination treatments for opioid crisis |
| PCT/US2019/014659 WO2019147606A1 (en) | 2018-01-26 | 2019-01-23 | Combination treatments for opioid crisis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020007860A true MX2020007860A (es) | 2020-09-03 |
Family
ID=67392667
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020007860A MX2020007860A (es) | 2018-01-26 | 2019-01-23 | Tratamientos combinados para crisis de opioides. |
Country Status (5)
| Country | Link |
|---|---|
| US (4) | US10478408B2 (es) |
| EP (1) | EP3743073A4 (es) |
| CA (1) | CA3089071A1 (es) |
| MX (1) | MX2020007860A (es) |
| WO (1) | WO2019147606A1 (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10478408B2 (en) | 2018-01-26 | 2019-11-19 | Michael Presti | Combination treatments for opioid crisis |
| EP3946547B1 (en) | 2019-03-26 | 2026-03-25 | Pinova Therapeutics Inc. | Devices and methods for delivering pharmaceutical compositions |
| US11278709B1 (en) | 2021-03-12 | 2022-03-22 | Pocket Naloxone Corp. | Drug delivery device and methods for using same |
| WO2023177841A2 (en) * | 2022-03-18 | 2023-09-21 | Presti Michael | Combination products to mitigate misuse of central nervous system stimulants |
| EP4687897A2 (en) * | 2023-04-04 | 2026-02-11 | Board of Regents, The University of Texas System | Combinations including methocinnamox |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5140032A (en) * | 1990-10-01 | 1992-08-18 | Radecki Thomas E | Drug therapy for alcohol abusers |
| CA2414500A1 (en) | 2002-12-17 | 2004-06-17 | Purepharm Inc. | Agonist-aversive combination medicines |
| US8791093B2 (en) | 2009-05-29 | 2014-07-29 | Lance L. Gooberman | Pharmaceutical delivery systems for treatment of substance abuse and other addictions |
| US10478408B2 (en) | 2018-01-26 | 2019-11-19 | Michael Presti | Combination treatments for opioid crisis |
-
2018
- 2018-01-26 US US15/881,475 patent/US10478408B2/en active Active
-
2019
- 2019-01-23 MX MX2020007860A patent/MX2020007860A/es unknown
- 2019-01-23 WO PCT/US2019/014659 patent/WO2019147606A1/en not_active Ceased
- 2019-01-23 EP EP19744389.8A patent/EP3743073A4/en not_active Withdrawn
- 2019-01-23 CA CA3089071A patent/CA3089071A1/en active Pending
- 2019-10-10 US US16/598,509 patent/US10881625B2/en active Active
-
2020
- 2020-11-23 US US17/102,010 patent/US11786490B2/en active Active
-
2021
- 2021-09-20 US US17/479,308 patent/US12036192B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20200038346A1 (en) | 2020-02-06 |
| US10881625B2 (en) | 2021-01-05 |
| US10478408B2 (en) | 2019-11-19 |
| EP3743073A1 (en) | 2020-12-02 |
| US20210161835A1 (en) | 2021-06-03 |
| US12036192B2 (en) | 2024-07-16 |
| US20220000809A1 (en) | 2022-01-06 |
| CA3089071A1 (en) | 2019-08-01 |
| EP3743073A4 (en) | 2021-11-03 |
| US20190231719A1 (en) | 2019-08-01 |
| WO2019147606A1 (en) | 2019-08-01 |
| US11786490B2 (en) | 2023-10-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ777261A (en) | Combination of dextromethorphan and bupropion for treating depression | |
| NZ700623A (en) | Botulinum toxin dosage regimen for chronic migraine prophylaxis | |
| MX343867B (es) | Paquete de dosificacion unitaria y metodos para administrar medicaciones de perdida de peso. | |
| AR124500A2 (es) | Aumento de la biodisponibilidad de droga en terapia naltrexona | |
| NZ604029A (en) | Methods of treating bladder cancer | |
| MX2009005339A (es) | Suspensiones analgesicas de liberacion modificada. | |
| NZ748650A (en) | Use of an anti-pd-1 antibody in combination with an anti-cd30 antibody in lymphoma treatment | |
| AR097619A1 (es) | Uso de inhibidores de acetil-coa carboxilasa para tratar acné vulgaris | |
| NZ744233A (en) | Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack | |
| MX2016007370A (es) | Agente terapeutico y/o preventivo que comprende un derivado de 1-indansulfamida para el dolor. | |
| IS2630B (is) | Meðferð á fráhvarfseinkennum | |
| AR052880A1 (es) | Metodo para tratar dolor visceral | |
| MX359672B (es) | Metodo para manejo de dolor cronico y tratamiento usando hcg. | |
| Konuganti et al. | Pre-emptive 8 mg dexamethasone and 120 mg etoricoxib for pain prevention after periodontal surgery: a randomised controlled clinical trial | |
| Chotton et al. | The effect of pregabalin for relief of postoperative pain after abdominal hysterectomy | |
| TW201642906A (en) | Fixed dose combination for pain relief without edema | |
| McKellar et al. | Update on the use of analgesics versus nonsteroidal anti-inflammatory drugs in rheumatic disorders: risks and benefits | |
| HK1244231A1 (zh) | 使用hcg治疗慢性疼痛的方法和治疗 | |
| AR105087A1 (es) | Métodos para el tratamiento de mujeres con trastorno de deseo sexual hipoactivo (hsdd) con el tratamiento de combinación bupropión y trazodona | |
| CL2011002863A1 (es) | Uso de una composicion que comprende nandrolona y un compuesto de vitamina d para preparar un medicamento parenteral util para el tratamiento o prevencion de la fragilidad en un paciente de edad avanzada; y composicion que comprende nandrolona y un compuesto de vitamina d, en un portador liquido adecuado para administracion parenteral. | |
| IN2014DN06117A (es) | ||
| Butenko et al. | “Pharmaceutical addiction”–consequences of alternative application of medicines | |
| MX357376B (es) | Composicion farmaceutica para uso en inflamacion y dolor. | |
| UA94010U (uk) | Спосіб лікування аденоміозу у жінок | |
| Stevens et al. | A Retrospective Analysis of the Effects of Transversus Abdominis Plane Blocks With and Without Analgesic Ketamine in Multimodal Analgesia Regimens for Total Abdominal Hysterectomy Surgery |